

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been:

- accepted for use in the NHSScotland by the Scottish Medicines Consortium (SMC), and/or
- accepted for use by the NHS board's Area Drug and Therapeutics Committee (ADTC).

How does the NHS board decide which new medicines to make available for patients?

Each NHS board has an ADTC. The ADTC is responsible for advising the NHS board on all aspects of the use of medicines. ADTCs take account of national and, where applicable, local guidance when deciding which medicines should be routinely available.

What national guidance does the ADTC consider?

- SMC advises on the use of newly licensed medicines in NHSScotland. In the table, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example Healthcare Improvement Scotland provides advice on some health technology assessments, including National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs).

What local guidance does the ADTC consider?

- Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each NHS board provide advice to their ADTCs on which medicines can be routinely used. Sometimes clinical experts decide that established medicines are a better choice than new medicines.
- Medicines routinely available for use within an NHS board are usually included in the 'local formulary'. The formulary is a list of medicines for use in the NHS board that has been agreed by ADTC in consultation with local clinical experts. The formulary encourages prescribers to become familiar with a limited list of medicines which can be used to treat the majority of medical conditions.

What if a particular medicine is not routinely available in my NHS board?

- This is usually because the medicine has not been accepted by SMC for use in NHSScotland.
- There may also be differences in which medicines are preferred in NHS boards. If SMC accepts a number of medicines for which there are other medicines already available to treat a specific medical condition, the NHS board's decision may depend on clinical experts' preferences and experiences with the medicine in their local population and on local prescribing guidance. If a decision is made for a medicine not to be routinely prescribed, there are usually alternative medicines available on the formulary.
- If a medicine is not routinely available and there are no suitable formulary alternatives, a doctor can make a request to prescribe the medicine if they believe it will benefit an individual patient. All NHS boards have procedures in place to consider individual requests when a doctor considers that a medicine not included on the formulary would be the best treatment option for an individual patient.

The following table lists the NHS board's decisions on new medicines.

If you need more information on medicines decisions in your NHS board area, please email hcis.adtc-collaborative@nhs.net

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Adalimumab sub-cutaneous injection Humira® 1173/16	Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08). http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1173_16_adalimumab_Humira/adalimumab_Humira	Not available as not recommended for use in NHSScotland	22/08/2016
Afatinib tablets Giotrif® 1174/16	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1174_16_afatinib_Giotrif/afatinib_Giotrif	Not available as not recommended for use in NHSScotland	22/08/2016
Alirocumab pre-filled pen Praluent® 1147/16	adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 10/10/2016	22/08/2016
Azacitidine injection Vidaza® 1175/16	Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1175_16_azacitidine_Vidaza/azacitidine_Vidaza	Not available as not recommended for use in NHSScotland	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Brivaracetam tablets, oral solution, injection/infusion Briviact® 1160/16	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1160_16_brivaracetam_Briviact/brivaracetam_Briviact	Available in line with national guidance	22/08/2016
Canagliflozin, dapagliflozin, empagliflozin oral MTA 390	as monotherapy for type 2 diabetes in adults for whom use of metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control https://www.nice.org.uk/guidance/ta390	Available in line with national guidance	22/08/2016
Crizotinib hard capsules Xalkori® 1152/16	First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1152_16_crizotinib_Xalkori/crizotinib_Xalkori	Available in line with regional guidance for prescribing	22/08/2016
Diamorphine hydrochloride nasal spray Ayendi® 1172/16	Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1172_16_diamorphine_hydrochloride_Ayendi/diamorphine_hydrochloride_Ayendi	Available in line with national guidance	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Elotuzumab infusion Empliciti® 1183/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1183_16_elotuzumab_Empliciti/elotuzumab_Empliciti	Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.	Not available as not recommended for use in NHSScotland	22/08/2016
Emtricitabine/tenofovir alafenamide tablets Descovy® 1169/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1169_16_emtricitabine_tenofovir_alafenamide_Descovy/emtricitabine_tenofovir_alafena	In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.	Available in line with national guidance	22/08/2016
Human alpha1-proteinase inhibitor infusion Respreeza® 1157/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1157_16_human_alpha_1_proteinase_inhibitor_Respreeza/human_alpha_1_proteinase	Maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor (A1-PI) deficiency.	Not available as not recommended for use in NHSScotland	22/08/2016
Ibrutinib hard capsules Imbruvica® 1151/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1151_16_ibrutinib_Imbruvica_CLL/ibrutinib_Imbruvica_CLL	Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.	Available in line with regional guidance for prescribing	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Ibrutinib hard capsules Imbruvica® 1150/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1150_16_ibrutinib_Imbruvica_MCL/ibrutinib_Imbruvica_MCL	Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	Available in line with regional guidance for prescribing	22/08/2016
Insulin degludec pre-filled pen, cartridge Tresiba® 856/13 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/856_13_insulin_degludec_Tresiba/insulin_degludec_Tresiba_2nd_Resubmission	Treatment of diabetes mellitus in adults	Available in line with local guidance for prescribing	22/08/2016
Levofloxacin nebuliser solution Quinsair® 1162/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1162_16_levofloxacin_Quinsair/levofloxacin_Quinsair	Management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.	Available in line with national guidance	22/08/2016
Necitumumab infusion Portrazza® 1184/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1184_16_necitumumab_Portrazza/necitumumab_Portrazza	In combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.	Not available as not recommended for use in NHSScotland	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Nivolumab infusion Opdivo® 1120/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/nivolumab_Opdivo_Resubmission	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Available in line with regional guidance for prescribing	22/08/2016
Nivolumab infusion Opdivo® 1144/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1144_16_nivolumab_Opdivo_for_metastatic_squamous_NSCLC/nivolumab_Opdivo_for	Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Available in line with regional guidance for prescribing	22/08/2016
Ramucirumab infusion Cyramza® 1176/16 http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1176_16_ramucirumab_Cyramza/ramucirumab_Cyramza	<ul style="list-style-type: none"> - In combination with paclitaxel for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy - As monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate 	Not available as not recommended for use in NHSScotland	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Rilpivirine tablet Edurant® 1168/16	In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1168_16_rilpivirine_hydrochloride_Edurant/rilpivirine_hydrochloride_Edurant	Available in line with national guidance	22/08/2016
Secukinumab sub-cutaneous injection Cosentyx® 1167/16	alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1167_16_secukinumab_Cosentyx/secukinumab_Cosentyx	Available in line with national guidance	22/08/2016
Secukinumab sub-cutaneous injection Cosentyx® 1159/16	Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1159_16_secukinumab_Cosentyx_AS/secukinumab_Cosentyx	Available in line with national guidance	22/08/2016
Vortioxetine tablets Brintellix® 1158/16	Treatment of major depressive episodes in adults. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1158_16_vortioxetine_Brintellix/vortioxetine_Brintellix	Not routinely available as local clinical experts do not wish to add the medicine to formulary at this time or there is a local preference for alternative medicines	22/08/2016